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Purpose. To describe frequency, clinical characteristics, and visual prognosis of tubercular uveitis (TBU) in a nonendemic country.
Methods. We retrospectively reviewed 3743 charts of patients with endogenous uveitis visited from 2008 to 2018 at a tertiary
referral centre in Rome, Italy. We included immunocompetent patients with diagnosis of TBU. Patients were divided in two
groups: patients with history of uveitis without a previous diagnosis of TBU (group A) and patients at their first episode of TB
uveitis (group B). Results. TBU was diagnosed in 28 (0.75%) out of 3743 patients. Twelve (42.9%) patients came from tuberculosis
endemic areas. All patients received specific antitubercular treatment (ATT) and were evaluated for a mean follow-up of 3.2± 2.9
years. Group A showed a greater number of ocular complications when compared with group B. ATTwas effective in reducing the
frequency of recurrences of uveitis in patients of group B. Conclusion. Intraocular inflammation can be the first manifestation of
tuberculosis. Our data highlight that early diagnosis and specific treatment of TBU may allow to decrease recurrences and to
improve visual outcomes.
1. Introduction
Tuberculosis (TB) is an infective disease caused by Myco-
bacterium tuberculosis (MT) or by other members of the
MT complex, and it represents one of the main causes of
mortality and morbidity in the world [1]. Tuberculosis is
characterized by pulmonary and extrapulmonary manifes-
tations which may involve the skin, eye, and nervous, car-
diovascular, gastrointestinal, or genitourinary systems [2].
(e main manifestation of ocular TB is uveitis. (e prev-
alence of TB uveitis (TBU) is estimated between 9% and 11%
in endemic countries and between 1% and 6% in non-
endemic countries [3–6]. In Italy, the frequency of TBU is
estimated to be approximately 7% [7, 8].
Intraocular TB is rare in active lung TB, while it is more
frequent in patients with advanced tubercular lesions or
extrapulmonary forms [9]. Trauma, immunosuppression,
and malnutrition are predisposing factors for development
of intraocular TB [10]. (e pathogenesis of ocular
involvement in TB is controversial. It has been supposed that
TBU may result from direct mycobacterium infection and/
or from a delayed hypersensitivity reaction to mycobacterial
antigens [11].
(e diagnosis and management of TBU represent a
challenge for ophthalmologists, due to the high variability of
clinical manifestations, poor associated systemic signs and
lack of consensus on specific treatment. Specifically, results
are controversial about the specific anti-TB treatment (ATT)
in patients with TBU [6, 12]. (e most frequent ATT for
patients with TBU is the use of four drugs (Isoniazid, Ri-
fampicin, Ethambutol, and Pyrazinamide) for 2 months
followed by two drugs, Rifampicin and Isoniazid, for 4
months [13–15]. In addition, patients with TBUmay develop
ocular complications which require specific treatments, such
as corticosteroids for cystoid macular edema (CME) or
ocular surgery in patients with cataract [16–18].
Few data are available on clinical presentation, man-
agement, and outcomes of TBU in nonendemic countries,
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including Italy. Cimino et al. described the course and
clinical outcomes of TBU in an Italian population and re-
ported that specific ATT was effective in reducing the
number of uveitis relapses and to improve visual outcome
[19].
Currently, no data are available on the effect of early
ATT on long-term clinical outcomes in patients with TBU.
(erefore, the aim of this study is to describe clinical and
epidemiological characteristics of patients with TBU re-
ferred at a tertiary eye centre in Rome, Italy, in order to
evaluate the effects of an early diagnosis and specific ATTon
visual outcomes and recurrence rate.
2. Materials and Methods
(e clinical charts of all patients referred at a tertiary referral
uveitis centre, the Ocular Immunovirology Service, at
Sapienza University of Rome, from January 1st, 2008, to
December 31st, 2018, were retrospectively reviewed. (e
study was performed in accordance with the tenets of the
Declaration of Helsinki, and Institutional Review Board
approval was obtained.
(e inclusion criteria were as follows:
(1) Diagnosis of uveitis, with or without involvement of
the optic nerve
(2) Positive tuberculin skin test (TST) (>10mm at 72 h)
and, in doubtful cases, positive interferon gamma
release assay (IGRA), including the QuantiFERON-
TB Gold.
(3) Specific treatment with antituberculosis treatment
during follow-up
We excluded patients with other syndromes or infec-
tions or acquired immunodeficiency syndrome and patients
in which diagnosis of TB was excluded based on results of
clinical evaluation, TST, IGRA tests, and chest imaging.
Diagnosis of TBU was performed by a uveitis specialist,
based on clinical history and complete eye examination, and
supported by diagnostic exams, including TST and IGRA
tests and chest radiography or contrast-enhanced computed
tomography (CT) scan.
Ocular and systemic clinical history and results of
complete eye exam were recorded, including visual acuity
assessment by Snellen charts, slit lamp examination, in-
traocular pressure (IOP) values assessed by Goldman
applanation tonometer, and fundus examination. In pos-
terior and diffuse uveitis, retinal vascularization was eval-
uated by Fluorangiography (FA), and macular morphology
was studied by Spectral Domain Optical Coherence To-
mography (SD-OCT, Heidelberg Spectralis, Heidelberg
Engineering, Heidelberg, Germany).
Uveitis was classified as anterior, intermediate, posterior,
and diffuse uveitis, in accordance with the International
Uveitis Study Group diagnostic criteria [20].
Clinical course, recurrence rate of uveal inflammation,
ocular complications, and visual acuity were evaluated
during the entire follow-up period. All topical and systemic
therapies, side effects of systemic treatments, and ocular
surgery performed during the follow-up period were also
collected.
To evaluate the effects of early diagnosis and specific
ATT on clinical and visual outcomes, patients were divided
in 2 groups based on their clinical history at the first visit in
our centre. Specifically, patients with diagnosis of uveitis
from at least 1 year, without previous etiological diagnosis of
TBU and not treated with specific ATT, were included in
group A. Patients at their first episode of uveitis, with a
diagnosis of TBU treated with ATT at the onset, were in-
cluded in group B.
(e following ocular parameters were compared be-
tween groups: (i) visual acuity, (ii) number of ocular re-
currences of TBU, and (iii) ocular complications.
(e exact Fisher test and independent t-test were used to
compare data in between groups. (e paired samples T-test
was used to evaluate changes in BCVA within groups. P
values< 0.05 were considered statistically significant (SPSS
version 24).
3. Results
In this retrospective study were included 28 (0.75%) patients
with TBU out of 3743 patients with uveitis visited in our
center, from 2008 to 2018. (e mean age of patients with
TBU was 48.8± 16.3 years (range 14–80 years). Sixteen were
females (57.1%) and 12 males (42.9%). Twelve (43%) out of
28 patients came from endemic countries for TB, and 16
patients (57%) were born in Italy. Anterior uveitis was the
most frequent form of uveitis, observed in 12 patients (43%),
2 of which were granulomatous uveitis. Diffuse uveitis was
observed in 9 patients, 4 of which were granulomatous, while
7 showed a posterior uveitis (Table 1). Sixteen uveitis were
bilateral (57%) and 12 monolateral (43%). Among the pa-
tients with posterior uveitis, 5 (71%) were Caucasian white
and 2 (29%) were Asian. Demographic and clinical char-
acteristics of patients included in the study are described in
Table 1.
All patients showed positive (>10mm after 72 h) TST.
(e QuantiFERON-TB-Gold test was performed in 11 pa-
tients and resulted positive in all cases. A chest radiography
was performed in all patients and showed an active pul-
monary lesion in 1 patient (4%), no visible pulmonary le-
sions in 13 (46%), and lung calcific nodules in 14 (50%)
cases. Ten patients (36%) underwent additional chest CT
scan, showing the presence of lung lesions in 8 cases, with an
active lesion in 1 patient.
Twelve patients (20 eyes) with TBU were referred to our
centre with a diagnosis of uveitis of unknown aetiology in
the previous 1–39 years (mean 11.8± 12.7 years). Sixteen
patients (24 eyes) at their first episode of TBU were included
in group B.
Seven (58%) patients included in group A showed an-
terior uveitis, 1 showed posterior uveitis, and 4 (33%)
showed diffuse uveitis. In the patients at their first episode of
TBU (group B), we observed posterior uveitis in 38% of
cases, followed by anterior (31%) and diffuse uveitis (31%)
(Figure 1).
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Eighteen (64%) out of 28 patients received standard
fourfold ATT for TB, including Isoniazid 5mg/kg/die, Ri-
fampicin 600mg/die, Ethambutol 15mg/kg/die, and Pyr-
azinamide 25–30mg/kg/die. Seven patients were treated
only with Isoniazid 5mg/Kg/die. Rifampicin 600mg/die was
prescribed in one case of panniculitis. Two patients were
treated for MDR forms. Because of high toxicity of anti-TB
drugs, liver and kidney function were regularly monitored
with periodic blood exams. A slight increase of hepatic
function indexes was observed in 1 patient during TB
therapy, which did not require ATT discontinuation. Side
effects of ATT included 1 optic neuritis due to treatment
with Ethambutol, 1 gastric intolerance which resulted in the
replacement of standard ATT with Moxifloxacin and Eth-
ambutol, and 1 case of anaemia, treated with oral iron
supplementation. Two patients reported skin rashes and
were treated with systemic antihistamines. (e character-
istics of specific treatment in the two groups are described in
Table 2. During the follow-up period, patients underwent
periodic eye examinations in our centre.
Patients with posterior uveitis were treated with oral
corticosteroids (prednisolone 1mg/kg) associated with
periocular corticosteroids injections (methylprednisolone
40mg/ml) in 2 cases. Patients with diffuse uveitis received an
association of mydriatic eye drops and local and systemic
corticosteroids.
Patients were periodically evaluated during ATT, and at
the end of treatment, in order to evaluate ocular compli-
cations and TBU relapses. (e mean follow-up was 3.2± 2.9
years (range: 1–11.3 years), 4.2± 3.1 years in group A, and
2.3± 2.6 years in group B. Ocular complications of TBU
were observed in 10 patients, 4 (25%) in group A, and 6
(60%) in group B (Table 1).
Cystoid macular edema was treated with oral acetazol-
amide and oral steroids. All patients with cataract underwent
cataract surgery. Glaucoma was treated with topical medical
therapy in 2 patients. Only one patient required surgical
iridectomy in addition to topical medications for glaucoma.
Mean best correct visual acuity (BCVA) before ATTwas
not different between the two groups (group A: 0.5± 0.38;
group B: 0.67± 0.4 decimal units). After specific ATT, group
B showed a significant improvement of mean BCVA (group
B: mean BCVA: 0.8± 0.38 p � 0.016 vs. baseline), while
patients in group A did not show a significant improvement
of BCVA (group A mean BCVA after ATT 0.48± 0.38). In
addition, improvement of BCVA was significantly higher in
group B (mean BCVA change from baseline 0.12± 0.23
decimal units), when compared with group A (mean BCVA
change from baseline −0.03± 0.21; p � 0.024 decimal units)
(Figure 2).
After ATT, the number of recurrences of the uveitis in
group A was significantly lower (mean 0.35± 2 recurrences/
year) when compared with the period before the diagnosis of
TBU with ATT (mean 1.94± 2 recurrences/year; p> 0.001).
During follow-up, after ATT, 5 (42%) patients in Group A
showed recurrence of TBU and only 1 patient in group B
(6%).
4. Discussion
(is retrospective study showed that the proportion of TB
uveitis among patients referred to our tertiary eye care centre
from 2008 to 2018 was 0.75%. (e frequency of TBU in our
center is decreased when compared with the previous studies
(1.76% in the period between 1986 and 1999 and 1.74%
between 1999 and 2003) [21].(is slight decrease of incidence
of TBU may reflect the trend of incidence of the disease, and
alternatively, it may be explained by an improvement of
diagnostic techniques, which allows to correctly diagnose
uveitis associated with sarcoidosis, histoplasmosis, and other
autoimmune diseases, that, in the past, were classified as TBU
[22, 23]. Our diagnosis of TBU was based on the presence of
clinical signs of uveitis associated with positive TST (>10mm
at 72 h) and/or IGRA tests and exclusion of other causes of
uveitis. (ere is a lack of consensus on the diagnostic criteria
of TBU. Gupta et al. proposed a classification of intraocular
TB (IOTB) as “confirmed,” “probable,” or “possible” [24].
(ey defined “confirmed IOTB” ocular inflammation asso-
ciated with a positive microbiological test for Mycobacterium
tuberculosis in ocular fluids (aqueous humor or vitreous) or
tissues [24]. However, vitreous and ocular tissues are difficult
Table 1: Demographic characteristics, uveitis features, and ocular
complications of the patients included in this study.
Variable All patients Group A Group B
Patients (n) 28 12 16
Male (n; %) 12 (42.9%) 5 (41.7%) 7 (43.7%)
Female (n, %) 16 (57.1%) 7 (58.3%) 9 (56.2%)
Age (mean± SD) 48.79± 16.26 58.83± 11.7 41.25± 15.31
Country of origin
Bangladesh 3 3
Bulgaria 1 1
Egypt 1 1
India 1 1
Italy 16 10 6
Morocco 1 1
Moldavia 1 1
Nigeria 1 1
Pakistan 1 1
Romania 2 2
Monolateral uveitis
(n; %) 12 (43%) 4 (33%) 8 (50%)
Bilateral uveitis (n; %) 16 (57%) 8 (66%) 8 (50%)
Anterior uveitis (n; %) 12 (43%) 7 (58%) 5 (31%)
Posterior uveitis (n; %) 7 (25%) 1 (9%) 6 (38%)
Diffuseuveitis (n; %) 9 (32.1%) 4 (33%) 5 (31%)
TBU complications
(n; %) 10 (36%) 4 (25%) 6 (60%)
CME (n) 3 3
Cataract (n) 2 2
Glaucoma (n) 1 1
CME and cataract (n) 2 2
CME and
glaucoma (n) 1 1
Glaucoma and
cataract (n) 1 1
n: number; SD: standard deviation; TBU: tubercular uveitis, CME: cystoid
macular edema.
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to collect, and microbiological test for Mycobacterium tu-
berculosis in aqueous humor are frequently false negative.
“Probable IOTB” was defined in cases in which uveitis is
associated with pulmonary or extrapulmonary active TB,
positive chest X-ray or immunologic tests for TB, or response
to ATT, and other aetiologies of uveitis are excluded [24]. An
intraocular inflammation is considered “possible IOTB” in
the presence of ocular signs suggestive of TBU, associated
with positive TSTor IGRA, without pulmonary or extraocular
signs of TB infection. According to the Tuberculosis Com-
mittee of the Portuguese Society of Pulmonology and of
Ophthalmology, diagnosis of ocular TB could be performed
in the presence of ocular findings suggesting ocular TB as-
sociated with TST or IGRA positivity (≥10mm in immu-
nocompetent patients) or chest radiology signs of TB [25].
Recently, a group of 25 ophthalmic centres analysed several
clinical features in a larger cohort of TBU cases in order to
identify novel and more standardized management protocols
[26].
In our study, 42.9% of patients came from endemic areas,
of which 91.7% were under 65 years of age. Conversely,
57.1% of our population was born in Italy, with 68.8% under
65 years of age. (is finding is in line with the epidemio-
logical evidence of an earlier onset of the disease in endemic
areas [27].
In the population of this study, we observed significant
differences neither in the type of uveal involvement by TB, in
the granulomatous and nongranulomatous forms, nor in the
monolateral/bilateral presentation. By comparing patients in
group A and B, we observed that patients of group A showed
higher frequency of anterior uveitis, while no differences in
anatomical sites was observed in group B. (is finding may
suggest that tubercular aetiology should be investigated also
in patients with anterior uveitis.
After diagnosis and specific treatment with ATT, we
observed an improvement of symptoms and a reduction of
frequency of relapses. We treated most of the patients with
TBU with four drugs (Isoniazid, Rifampicin, Ethambutol,
and Pyrazinamide) for 2 months and subsequently with two
drugs, Rifampicin and Isoniazid, for 4 months. In line with
previous studies, the most frequent complication in our
study was CME [28].
(a) (b)
(c) (d)
Figure 1: Ophthalmoscopic and fluorescein angiographic (FA) images of a patient with posterior tubercular uveitis. Before treatment,
fundus photograph (a) and FA (b) show multiple cream-yellow active lesions with increase of choroidal fluorescence at FA. Twelve months
after antitubercular treatment, fundus photograph (c) and FA (d) show fading inactive lesions and mottling pigment (white arrow) with
decrease of choroidal fluorescence.
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(enecessity to treat TB uveitis with ATTis controversial.
Previous studies suggested that ATT treatment positively
influences ocular relapses, inducing a remission of the disease
in a higher number of patients, when compared with un-
treated group (84% and 58% of patients, respectively) [2, 26].
In line with these studies, in our population, 78% of patients
did not show relapses of the uveitis after ATT during the
entire follow-up period [2, 26].
La Distia Nora et al. reported that that ATT does not
influence visual prognosis after 1 year of follow-up in a
nonendemic country. However, this study evaluated all
ocular inflammation associated with the positive Quanti-
feron-TB Gold test, including uveitis and scleritis, in both
immunocompetent and immuno-deficient patients [29].
Brunner et al. also evaluated patients affected by retinal
vasculitis and positive TB gold in a nonendemic country
and concluded that fourfold treatment did not influence
the extension of vasculitis nor visual acuity, but was ef-
fective in reducing recurrences of ocular inflammation
[30]. A retrospective study in a uveitis centre of
Table 2: Antitubercular treatment in the two groups. (PYR� Pyrazinamide; ETHA�Ethambutol; RIF�Rifampicin; ISO� Isoniazid; and
CLA�Clarithromycin).
Patient (erapy Duration Side effects
Group A
1 ISO 6 months —
2 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
3 RIF 3 months —
4 ISO 2 months —
5 ISO 12 months —
6 PYR ETHA RIF ISOfollowed by RIF ISO
0.5 month
1 month Gastric intolerance
7 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
3 months —
8 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
9 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months Increase of blood liver enzymes
10 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
11 ISO 4 months —
12 ISO 8 months —
Group B
13 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
14 PYR ETHA RIF ISO Not compliant —
15 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
16 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months Optic neuritis
17 RIF ETHA AZT 12 months —
18 CLA ETHA 12 months —
19 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months Itching
20 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
21 ISO 5 months —
22 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
23 ISO Not compliant —
24 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months —
25 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months Itching
26 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
4 months Anemy
27 PYR ETHA RIF ISOfollowed by RIF ISO
2 months
2 months —
28 PYR ETHA RIF ISO 1 month —
Patients with anterior uveitis received topical ophthalmic treatment with mydriatic eye drops associated with topical dexamethasone 0.2% eye drops.
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Birmingham also reported that 6 months after ATT, 90% of
patients were flare free, and 80% were flare free at 12
months. (e authors also reported that patients treated
with ATT within 8 months of ocular onset did not show
significant difference in the time to flare-up when com-
pared with patients untreated for a longer time [31]. In
contrast, our data showed lower recurrence rate in the
group of patients which received an early treatment. In-
deed, we divided our population in two groups: group A,
including patients in which the etiological diagnosis of
TBU was not performed for long time and group B, in
which patients received a diagnosis of TBU at their first
episode of uveitis. Furthermore, we have evaluated the
difference in ocular recurrences and in visual outcomes
between the two groups, before and after ATT. We ob-
served that patients in Group B, treated with ATT at their
first episode of TBU, showed a higher improvement of
visual acuity, highlighting the importance of a prompt
diagnosis and an early specific treatment. (is finding is in
line with previous studies reporting the efficacy of ATT in
improving visual outcome [27, 32]. In addition, after ATT,
patients in group B showed a lower number of recurrences
during the follow-up when compared with group A. Re-
garding ATT tolerability, only 5 patients had some side
effects, which did not require discontinuation of treatment.
5. Conclusion
In conclusion, in this study, we demonstrate that early di-
agnosis and specific treatment for TBU allowed a decrease of
recurrences and a significant improvement of visual acuity.
Our results also highlight the importance of considering TB
as a possible cause of idiopathic uveitis, also in nonendemic
countries.
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